2003
Chapter 18 Chemoprevention of Oral Premalignant Lesions
Mayne S, Cartmel B, Morse D. Chapter 18 Chemoprevention of Oral Premalignant Lesions. 2003, 261-269. DOI: 10.1016/b978-012239990-9/50019-9.ChaptersOral precancerous lesionsOral premalignant lesionsPrecancerous lesionsChemoprevention trialsPremalignant lesionsOral premalignancyOral cancer preventionEfficacy of agentsPotential chemopreventive agentsDirect clinical relevancePharyngeal cancerChemoprevention researchChemopreventive efficacySpirulina fusiformisChemopreventive agentsClinical relevanceVitamin ELesionsClinical settingBiological markersSignificant toxicityChemopreventionEfficacySame agentsPrevention
2001
Predictors for cutaneous basal‐ and squamous‐cell carcinoma among actinically damaged adults
Foote J, Harris R, Giuliano A, Roe D, Moon T, Cartmel B, Alberts D. Predictors for cutaneous basal‐ and squamous‐cell carcinoma among actinically damaged adults. International Journal Of Cancer 2001, 95: 7-11. PMID: 11241303, PMCID: PMC2637530, DOI: 10.1002/1097-0215(20010120)95:1<7::aid-ijc1001>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaSkin cancerRisk factorsNon-melanoma skin cancerSCC incidence ratesAge 61 yearsRed hair colorGroup of menActinic lesionsBCC occurrencePlacebo groupChemoprevention trialsCutaneous basalBCC lesionsMale genderIncidence ratePrior historySun damageSubstantial incidenceOlder ageCancerFirst SCCExposure factorsAdult residenceCarcinoma
2000
Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study.
Cartmel B, Moon T, Levine N, Rodney S, Alberts D. Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study. Cancer Epidemiology Biomarkers & Prevention 2000, 9: 999-1002. PMID: 11008922.Peer-Reviewed Original ResearchConceptsCancer chemoprevention trialsChemoprevention trialsSkin cancer chemoprevention studiesFuture chemoprevention trialsIU of retinolCancer chemoprevention studiesLow education levelSkin cancer chemoprevention trialOnly significant predictorPlacebo groupChemoprevention studiesClinical symptomsUnmarried statusCommon reasonStudy capsulesTreatment groupsInactive participantsVitamin AGood complianceFirst monthTrialsSignificant predictorsNumber of participantsSignificant differencesSymptoms
1999
Predictors of participant retention in two chemoprevention feasibility trials
Bowen D, Cartmel B, Barnett M, Goodman G, Omenn G. Predictors of participant retention in two chemoprevention feasibility trials. Annals Of Behavioral Medicine 1999, 21: 210-215. PMID: 10626026, DOI: 10.1007/bf02884835.Peer-Reviewed Original ResearchConceptsPilot study participantsPilot studyClinical trialsEfficacy trialsStudy participantsLong-term clinical trialsAsbestos-exposed participantsRetinol Efficacy TrialAsbestos-exposed workersHigh blood pressureCancer chemoprevention trialsGeneral health issuesFull-scale efficacy trialHigher baseline levelsMental health measuresRetention of participantsOnly significant predictorCurrent smokersBlood pressureChemoprevention trialsFeasibility trialPredictors of retentionPrevention StudyBaseline predictorsBaseline levelsEffects of long-term intake of retinol on selected clinical and laboratory indexes
Cartmel B, Moon T, Levine N. Effects of long-term intake of retinol on selected clinical and laboratory indexes. American Journal Of Clinical Nutrition 1999, 69: 937-943. PMID: 10232634, DOI: 10.1093/ajcn/69.5.937.Peer-Reviewed Original ResearchConceptsRetinol intakeAdverse effectsLaboratory indicesVitamin A/dCoronary artery disease riskCancer chemoprevention trialsLong-term ingestionMinimal adverse effectsLong-term intakeSkin cancer chemoprevention trialAlkaline phosphataseMedian followPlacebo groupChemoprevention trialsClinical symptomsRetinol groupChemopreventive agentsCholesterol concentrationsHealthy populationSkin cancerModerate riskDisease riskIntakeFurther studiesSignificant differences